Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar
PHASE3CompletedINTERVENTIONAL
Enrollment
339
Participants
Timeline
Start Date
November 30, 2007
Primary Completion Date
March 31, 2008
Study Completion Date
April 30, 2009
Conditions
Streptococcus Pneumoniae
Interventions
BIOLOGICAL
Pneumo 23
Vaccine (Pneumo 23)
BIOLOGICAL
Prevnar
Vaccine (Prevnar)
Trial Locations (2)
Unknown
Bangkok
KhonKaen
All Listed Sponsors
lead
Sanofi Pasteur, a Sanofi Company
INDUSTRY
NCT00594347 - Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar | Biotech Hunter | Biotech Hunter